Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.38 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14047158 | 1.00 | AAK1 (0.39) | AAK1ALDH1A1HTTCTSSCTSK | |
| SCHEMBL12634964 | 0.92 | AAK1 (0.41) | AAK1CTSSCTSKLTB4RMEN1 | |
| SCHEMBL12634967 | 0.92 | AAK1 (0.41) | AAK1CTSSCTSKLTB4RMEN1 | |
| SCHEMBL12635039 | 0.88 | SMN1; SMN2 (0.38) | AAK1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL12635061 | 0.88 | SMN1; SMN2 (0.38) | AAK1ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL12634681 | 0.88 | AAK1 (0.40) | AAK1CTSSCTSKLTB4RLTB4R2 | |
| SCHEMBL15291926 | 0.87 | CTSK (0.42) | HTTCTSSCTSKLTB4RLTB4R2 | |
| SCHEMBL12635392 | 0.86 | AAK1 (0.39) | AAK1CTSSCTSKLTB4RLTB4R2 | |
| SCHEMBL12635110 | 0.85 | CTSS (0.39) | AAK1ALDH1A1HTTCTSSCTSK | |
| SCHEMBL12635114 | 0.85 | CTSS (0.39) | AAK1ALDH1A1HTTCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | AAK1 2124/4885ALDH1A1 4297/4885HTT 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.